By Sherri Oslick --
Thrasos Therapeutics, a Hopkinton, MA based biotechnology company, announced earlier this week the issuance of U.S. Patent No. 7,482,329 ("Single Domain TDF-Related Compounds and Analogs Thereof," issued January 27, 2009) directed to small molecules that selectively activate the key receptors of the bone morphogenetic protein (BMP) family. BMPs are part of the TGF-β superfamily of proteins, and are implicated, via the SMAD signaling pathway, in the reduction and control of inflammation and fibrosis and in the prevention of apoptosis in many different cells, tissues, and organs. BMPs are also implicated in the stimulation of the growth of cartilage and bone.
The claimed compounds selectively target key receptors of the BMP family of proteins to specifically activate the repair and regenerative effects of BMP, without stimulating bone growth, providing cell and tissue protection, repair and regenerative treatment without bone growth stimulation. The compounds in particular offer promise in the treatment of Acute Kidney Injury and Chronic Kidney Disease.
Claim 1 of the patent recites:
SEQ ID NO.45 (H)-CYFDDSSNVLCKKYRS-(OH)
SEQ ID NO.33 (H)-CYFDDSSNVLCKKYRS-(NH2)
SEQ ID NO.24 (H)-CYFDDSSNVICKRYRS-(OH)
SEQ ID NO.43 (H)-CYFDDSSOVLCKKYRS-(OH)
Comments